CA
NZ
UK
AU
IND
US
Zymeworks (NASDAQ: ZYME) delivered earnings per share of $‑0.62 for the quarter ended June 30, missing the consensus forecast of $‑0.47. The earnings miss amplifies scrutiny on the company’s near‑term growth drivers, especially the pending $250 million zanidatamab approval milestone and the upcoming Theravance …
Revelation Biosciences, Inc. posted a net loss of $3.3 million for the second quarter of 2026, signaling a deterioration from the $2.4 million loss in the same period last year. This reflects a growing expense burden for the clinical-stage company as it advances its …
This performance aligns with analysts’ consensus for an EPS loss of $-0.02. Improved gross margins did not compensate for the lower sales volume, prompting management to highlight ongoing pressure in the market.
STERIS plc (NYSE: STE) enlarged its board on May 5, 2026, moving from nine to ten seats and bringing Pierre Boulud aboard as a director. The board expansion signals a deliberate effort to deepen oversight at a time when the firm’s market capitalisation stands …
The company generated total net sales of $72.1, split between $18.3 in delivery‑system revenue and $53.9 in consumables revenue. Both categories posted lower figures compared with the previous year’s $22.4 delivery‑system and $55.8 consumables sales.
STAAR Surgical Company (NASDAQ: STAA) has elevated Warren Foust to President and Chief Executive Officer, solidifying its leadership structure with a compensation package heavily weighted toward share price performance. Foust, who had been serving as Interim Co-CEO, assumes the permanent role effective August 4, …
Tango Therapeutics (NASDAQ: TNGX) announced the termination of Dr. Barbara Weber’s employment as Executive Chair effective Aug 3 2026, coupling the exit with a severance package that continues her base salary through Dec 31 2026 and accelerates vesting of outstanding stock options and restricted …
The beat provides a tangible proof point for investors monitoring the company’s ability to manage cost growth while advancing its pipeline, a factor that can influence valuation multiples amid a volatile biotech sector.
ProPhase Labs, Inc. (OTC: PRPH) has entered a significant financial arrangement with J.J. Astor & Co. securing a convertible loan valued at $2.08 million. The company received net proceeds of approximately $1.02 million after deducting fees.
Prothena (NASDAQ: PRTA) reported earnings per share of $‑0.32 for the quarter ended June 30, outpacing the $‑0.40 consensus and shrinking the quarterly net loss to $18.6 million. The result highlights a dramatic improvement from the $125.8 million loss recorded in the same quarter …
Please wait processing your request...